Randomized Controlled Study of the Efficacy of Hypnosis Versus Relaxation and Control in Neuropathic Pain
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuropathic Pain
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
The secondary objectives of this study are: to show a superiority of hypnosis and relaxation over control group on neuropathic pain. to show a lasting effect of treatment on neuropathic pain one week after the end of treatment. to evaluate the clinical predictors of response to hypnosis (nature of n...
The secondary objectives of this study are: to show a superiority of hypnosis and relaxation over control group on neuropathic pain. to show a lasting effect of treatment on neuropathic pain one week after the end of treatment. to evaluate the clinical predictors of response to hypnosis (nature of neuropathic symptoms, severity of anxiety and depressive symptoms, pain catastrophizing, coping strategies, emotional regulation, response to the first session, positive or negative emotional reaction at the end of hypnosis sessions). to evaluate the effect of hypnosis at long-term (1, 3 and 6 months after the end of treatment). to evaluate the effect of hypnosis on emotional processes. to compare hypnosis to relaxation on short-term effects on pain, to evaluate the quality of life and the impact of pain on daily life: sleep, mood, anxiety symptoms, analgesics consumption , neuropathic symptoms, affective component of pain and pain catastrophizing. 35 patients will be enrolled in each arm, to obtain 105 in total (3 arms). Total duration for each patient: 8 months.
Tracking Information
- NCT #
- NCT02256371
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Nadine ATTAL, MD, PhD Groupe Hospitalier Ambroise Paré